Trillium Therapeutics Inc (NASDAQ:TRIL)

8.77
Delayed Data
As of 3:59pm ET
 +0.125 / +1.45%
Today’s Change
5.73
Today|||52-Week Range
20.96
-40.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$891.1M

Company Description

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Contact Information

Trillium Therapeutics, Inc.
2488 Dunwin Drive
Mississauga Ontario L5L 1J9
P:(416) 595-0627
Investor Relations:
14165950627232

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Jan SkvarkaPresident, Chief Executive Officer & Director
James T. ParsonsChief Financial Officer
Robert A. UgerChief Scientific Officer
Ingmar BrunsChief Medical Officer
Penka PetrovaChief Development Officer